Remission Realized: Achieving Disease Control in Your Patients with Rheumatoid Arthritis : Episode 16
Closing Remarks
Panelists discuss how their approaches to treating patients with rheumatoid arthritis focus on personalized strategies that prioritize achieving remission while carefully monitoring safety and efficacy outcomes.
EP: 1.Intro and Welcomes
EP: 2.Evolving Goals in Rheumatoid Arthritis Treatment: Defining and Achieving Clinical Remission
EP: 3.Prevalence and Management of Poorly Controlled Rheumatoid Arthritis in Clinical Practice
EP: 4.Complications and Prognostic Factors in Uncontrolled Rheumatoid Arthritis
EP: 5.Evaluating and Adjusting Rheumatoid Arthritis Treatment: Adhering to ACR Guidelines for csDMARDs and Advanced Therapies
EP: 6.Exploring the Discrepancy Between Patient Perception and Disease Activity Assessments
EP: 7.Achieving Low Disease Activity and Remission: Managing Patient Expectations
EP: 8.Guidance on Transitioning from TNFi to Non-TNF Targeted Therapies
EP: 9.Advanced Treatment Options for RA: Exploring the Data
EP: 10.Guiding Treatment Decisions: The Role of Remission Data and Head-to-Head Comparisons
EP: 11.JAK Inhibitors vs TNF Inhibitors: Effects on Administration, Efficacy, and Safety
EP: 12.JAK Inhibitor Selectivity and Dose-Related Toxicity
EP: 13.Outcomes of Class Switching vs Cycling TNF Inhibitors
EP: 14.Cycling Within TNF Inhibitors: Complications and Factors Influencing Treatment Choices
EP: 15.Safety and Efficacy of Janus Kinase Inhibitors
Now Viewing
EP: 16.Closing Remarks
Video content above is prompted by the following:
Can each of you provide closing remarks on how you treat your own patients to achieve remission?
Recent Videos
Related Content
